Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Blinding a CYCLOPS

Published: Monday, August 20, 2012
Last Updated: Monday, August 20, 2012
Bookmark and Share
Targeted therapies are changing cancer treatment.

Designed to wield laser-like precision, they focus on overactive proteins produced by mutated genes, destroying cancer cells but sparing normal cells. Most of the cancer drugs created in the last decade follow that model, exploiting knowledge of genetic mutations to stop cancer’s progression rather than aiming a fusillade of chemotherapy agents against all fast-growing cells, normal or cancerous.

But many mutations do not make good targets. Tumor suppressor genes – which normally act like the brakes on runaway cell growth –– are the most commonly mutated genes in cancer, but they are notoriously difficult to target with current techniques. New targets are needed, driving cancer researchers to seek out new therapeutic approaches.

Looking back to a hypothesis first proposed soon after tumor suppressor genes were discovered, a team of scientists from the Broad Institute and Dana-Farber Cancer Institute present a new paradigm for attacking vulnerabilities in cancer cells by targeting genes that don’t necessarily contribute to cancer formation but are altered along the way to becoming cancer.

Nearly 20 years ago Dana-Farber researcher Emil Frei proposed that when tumor suppressor genes were mutated, they weren’t the only parts of the genome being damaged. When mutations disarmed tumor suppressors, they also cut a wider swath of genomic instability. Nearby genes might also be injured, although to a lesser extent. A tumor cell might lose one of its two copies of a nearby gene, for example. That lone copy might be sufficient for cell survival, but additional stress could be more than the cell could tolerate.

In 1993, there was no large-scale way to test this hypothesis. Now scientists led by Broad associate members Rameen Beroukhim and William C. Hahn have harnessed computational strength and biological expertise to answer the question. Writing in the August 15 online edition of Cell, they report proof of principle for a novel strategy that attacks cancer cells by targeting genes partially lost on the path to cancer.

“Cancers delete parts of their genomes when they get rid of tumor suppressor genes, but that process of deletion also makes them susceptible to stresses that otherwise normal cells could tolerate,” said co-senior author Hahn, who is also a medical oncologist at Dana-Farber and an associate professor of medicine at Harvard Medical School. “This discovery opens up a whole new universe of potential targets that seem to distinguish a large fraction of cancer cells from normal cells,” said Beroukhim, co-senior author, a medical oncologist at Dana-Farber, and an assistant professor of medicine at Harvard Medical School.

To systematically identify these genes, the researchers, including co-first authors Deepak Nijhawan and Travis I. Zack, integrated data sets from Project Achilles, which is a comprehensive catalog of genes essential for cancer cell survival, and the Cancer Cell Line Encyclopedia, which includes copy number data. Their analysis yielded 56 genes that had lost one of their two copies. They call them CYCLOPS genes, short for Copy-number alterations Yielding Cancer Liabilities Owing to Partial loSs. Like the mythical one-eyed giant, they depend on that one copy to survive.

The CYCLOPS genes were not randomly assorted throughout the genome. Instead, they largely fell into three complexes important for cell proliferation and survival: the proteosome, the spliceosome, and the ribosome. The scientists narrowed their focus to PSMC2, a gene in the proteasome that has lost one of its gene copies in 10 percent of all cancers. In all, four proteasome CYCLOPS genes were found in a combined 40 percent of cancers.

In normal cells, the proteasome works like a sophisticated garbage disposal to chew up and dispose of proteins that are misfolded or no longer needed. The protein encoded by PSMC2 helps form the cylindrical proteasome’s two caps on its top and bottom. When PSMC2 protein levels are suppressed in a normal cell, the cell calls on a reservoir of PSMC2 protein in the cell. The CYCLOPS version of PSMC2 is unable to supply enough to fill that reservoir in the cell, so when it runs dry, the proteasome stops working and the cell dies.

Using nanoparticle technology to deliver gene-silencing RNA interference, the scientists specifically targeted tumors in mice. When they knocked out PSMC2, tumors were reduced by more than 75 percent and overall survival doubled.

Beyond its cellular importance, the proteasome is also an appealing target because the cancer drug bortezomib, sold as Velcade, is a proteasome inhibitor with tolerable side effects. Its mechanism is not well understood, Hahn said.

“Our paper doesn’t tell us why bortezomib does or doesn’t work in certain cancers, but it does tell us there might be more sophisticated ways to attack the proteasome,” he said. “That might help us understand which patients might benefit.”

Showing that cancer cells are dependent on one CYCLOPS gene in the proteasome opens up new avenues for future work, starting with the proteasome, spliceosome (a splicer of messenger RNA), or ribosome (site of protein synthesis) and possibly beyond, Beroukhim said.

“This opens up a potentially large variety of vulnerabilities to attack in cancer cells,” he said. “There is still work to be done, but if this phenomenon can be taken advantage of therapeutically, it would have a potentially widespread application.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DARPA Awards $32 Million Contract to MIT, Broad Institute Foundry
A facility at the Broad Institute of MIT and Harvard and MIT that aims to achieve the full potential of engineering biology has received a five-year, $32 million contract from the Defense Advanced Research Projects Agency (DARPA).
Monday, September 28, 2015
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
Monday, September 28, 2015
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
Thursday, November 27, 2014
Targeting Cancer’s “Queen Bees” with Better Tissue Modeling
In many types of cancer, standard chemotherapy cures only a fraction of patients.
Wednesday, October 30, 2013
Understanding Triglycerides’ Role in Coronary Disease
The study leverages new genetic data from a related genome-wide association study, suggests that lowering triglyceride levels through treatment may help reduce the risk of coronary heart disease.
Wednesday, October 09, 2013
Better Living through Proteomics
As a patient facing illness, knowing what’s ailing you can bring peace of mind and, more importantly, can inform treatment decisions.
Monday, September 09, 2013
Target Set on Cancer Gene MCL1
Broad Institute and Dana-Farber colleagues identify several chemical compounds that tamp down the expression of the MCL1 gene.
Friday, June 15, 2012
Broad Institute, Dana-Farber and Novartis Collaborate to Develop Cancer Cell Line Encyclopedia
Scientists have written the 'Book of Cancer Knowledge' to aid future research into drug discovery and personalized medicine.
Friday, March 30, 2012
Scientific News
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos